News

The combination of ivuxolimab and utomilumab was well tolerated in patients with advanced solid tumors, according to a phase 1 study.

In an interview with Targeted Oncology, Nagaraj Nagathihalli, PhD, further explained the basis behind his study examining tobacco-associated pancreatic cancer and his plans to improve overall survival in this patient population.

Eytan M. Stein, MD, discusses the currently available treatment options for patients with acute myeloid leukemia and how Menin inhibitors fit into this space.

Findings from the phase 2 TheraP trial showed 177Lu-PSMA-617 to result in a higher prostate-specific antigen response rate vs with cabazitaxel in patients with metastatic castration-resistant prostate cancer.

While information has come out stating the negative effects of e-cigarettes on lung health, questions regarding the longer-term safety of these products remain due to their limited timespan on the market.

Fruquintinib plus paclitaxel demonstrated improvements in progression-free survival, objective response rate, disease control rate, and more, in patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Cyrus M. Kahn, MD, discusses the evolution of the treatment landscape for patients with mantle cell lymphoma.

Robert J. Soiffer, MD, discusses the use of transplant in various hematologic malignancies.

Randomized studies examining patients with peripheral T-cell lymphoma regarding the role of transplant are lacking and more research is needed to personalize therapy for patients based on subtype, biomarkers, mutational profiling, and radiographic parameters.

With the addition of eganelisib to atezolizumab plus nab-paclitaxel, patients with metastatic triple negative breast cancer have longer progression-free survival and better response vs atezolizumab and nab-paclitaxel alone.

A phase 1 trial evaluating 5-aminolevulinic acid and CV01 delivery of ultrasound has begun treating the first 3 of approximately 33 patients with recurrent high-grade glioma.

Treatment with CUE-101 continued to show promise for patients with head and neck squamous cell carcinoma when combined with pembrolizumab or used as a monotherapy.

Michael Diaz, MD, will participate as a panelist for the Patient-Centered Oncology Care conference presented by The American Journal of Managed Care on November 9 – 10, 2022 in Nashville, TN.

Mirvetuximab soravtansine has been granted FDA accelerated approval for use in patients with folate receptor alpha-high platinum-resistant ovarian cancer who have received prior treatment with 1 to 3 prior systemic therapies.

Alexander Spira, MD, PhD, FACP, discusses the rationale for combining amivantamab-vmjw and lazertinib for the treatment of relapsed or refractory EGFR-mutant non–small cell lung cancer.

Advanced treatments and technology for urologic disorders offered in one convenient location.

Based on OS data from the phase 3 ENGOT-OV16/NOVA trial, the FDA has requested niraparib to have restricted use as a second-line maintenance therapy for patients without germline BRCA mutations.

Toni K. Choueiri, MD, discusses a key next step for using pembrolizumab in the treatment of renal cell carcinoma.

Retrospective analysis of a phase 2 trial indicated that tivozanib demonstrated efficacy and tolerability in the subset of patients who had non-clear cell histologies of renal cell carcinoma.

The impressive POSEIDON clinical trial results have led to the FDA approval of tremelimumab in combination with durvalumab and platinum-based chemotherapy for the treatment of metastatic non–small cell lung cancer.

Based on results from the phase 3 AHOD1331 trial, the FDA has approved brentuximab vedotin in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide in pediatric patients with high-risk classical Hodgkin lymphoma.

Matthew P. Goetz, MD, discusses the background of the ELAINE-1 study examining lasofoxifene in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer harboring estrogen receptor 1 mutations.

The FDA has advised ADC Therapeutics that a randomized phase 3 confirmatory study is needed to support a future FDA approval for camidanlumab tesirine as treatment of relapsed or refractory Hodgkin lymphoma.

Part 2 of the NOVA-II phase 2 trial evaluating OQL011 has enrolled the first patient with cancer with VEGFR inhibitor-associated hand-foot skin reaction.

Results from a phase 3 study show that the continuous maintenance therapy of enzalutamide reduces the risk of disease progression in certain patients with metastatic castration resistant prostate cancer.

Ipsen plans to seek FDA approval for the NALIRIFOX regimen based on positive results from the phase 3 NAPOLI 3 clinical trial.

A first-in-human study investigating the safety and immunogenicity of amplivant adjuvant and human papillomavirus type 16 synthetic long peptides demonstrated highly favorable safety and tolerability when used as an intradermal therapeutic vaccine.

In an interview with Targeted Oncology, Tycel Phillips, MD, discussed the many treatment options available and those that are being examined for patients with mantle cell lymphoma in the second-line setting.